Skip to content

Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug Phenprocoumon

Prospective Randomized Trial of a Clinical Algorithm to Predict the Loading Dose of Phenprocoumon

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00586287
Enrollment
302
Registered
2008-01-04
Start date
2007-01-31
Completion date
2011-12-31
Last updated
2012-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Hip Replacement Postoperative, Knee Replacement Postoperative, Pulmonary Embolism

Keywords

Phenprocoumon, Dosing algorithm, loading dose

Brief summary

Oral anticoagulation is often initiated in hospitalized patients. Although the therapeutic range of phenprocoumon is narrow, the individual drug demands unfortunately vary greatly between persons. Our group recently developed two dosing algorithms for the initiation of anticoagulation based on clinical predictors such as age, gender, body weight and laboratory values. The aim of the proposed study is to prospectively evaluate the efficacy and safety of these two algorithms in medical and orthopedic inpatients, as well as in a group of outpatients and possibly in a geriatric collective.

Detailed description

Background: The presently available oral anticoagulants have a very narrow therapeutic range but the interindividual demands to achieve therapeutic anticoagulation (=loading dose) varies greatly. Overanticoagulation is a major cause of bleeding complications, whereas insufficient anticoagulation is associated with thromboembolic disease and possibly prolonged hospital stay. A model to predict the loading dose with phenprocoumon (Marcoumar®) is therefore highly desirable. In a retrospective analysis of 300 inpatients (152 medical, 148 orthopedic patients) of the Cantonal Hospital of St. Gallen our group identified clinical predictors for the loading dose of phenprocoumon and two dosing algorithms were developed (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.). In order to validate the safety and efficacy of these dosing algorithms we plan this prospective interventional study with three equally sized arms: dosing according to algorithm 1, dosing according to algorithm 2 or dosing according to the estimate of the physician (control).

Interventions

OTHERAlgorithm for phenprocoumon

Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm A published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)

OTHERalgorithm for phenprocoumon

Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm B published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)

Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according to the discretion of the treating physician

Sponsors

Cantonal Hospital of St. Gallen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Consecutive inpatients of the internal medicine and the orthopedic surgery department of the Cantonal Hospital of St. Gallen needing new onset oral anticoagulation

Exclusion criteria

* Patients with prior oral anticoagulation with coumarines within less than 6 weeks, * patents, who received vitamin-K supplements within less than one week before the onset of oral anticoagulation, * patients with liver cirrhosis other than Child A, * pregnant women (pregnancy has to be excluded in women of childbearing age), * patients younger than 18 years, and * patients unwilling or unable to give informed consent * patients with (clinically diagnosed) dementia and * persons with insufficient German, French, Italian or English language skills)

Design outcomes

Primary

MeasureTime frame
rate of patients with therapeutic INR levels on day six without anticoagulation-related complications during the loading periodafter 30 days

Secondary

MeasureTime frame
the time-course of the INR-values, the rate of excessive INR-values, defined as INR >3.5 within 10 days, the rate of minor and major bleeding complications, the length of stay, and death within 30 days30 days

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026